Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 23 May 2014 |
| Multiple Daratumumab Abstracts to be Presented at EHA | 22 May 2014 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 15 May 2014 |
| Articles of Association for Genmab A/S | 15 May 2014 |